1. Home
  2. CXM vs LTGO Comparison

CXM vs LTGO Comparison

Compare CXM & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sprinklr Inc.

CXM

Sprinklr Inc.

HOLD

Current Price

$6.11

Market Cap

1.4B

Sector

Technology

ML Signal

HOLD

LTGO

Latigo Biotherapeutics Inc. Common Stock

N/A

Current Price

$14.25

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CXM
LTGO
Founded
2009
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.2B
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
CXM
LTGO
Price
$6.11
$14.25
Analyst Decision
Hold
Strong Buy
Analyst Count
9
4
Target Price
$8.44
★ $52.25
AVG Volume (30 Days)
★ 2.3M
298.0K
Earning Date
12-02-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 0.05
N/A
Revenue
★ $857,200,000.00
N/A
Revenue This Year
$1.19
N/A
Revenue Next Year
$3.46
N/A
P/E Ratio
$116.70
★ N/A
Revenue Growth
★ 7.64
N/A
52 Week Low
$4.72
$13.50
52 Week High
$8.28
$25.93

Technical Indicators

Market Signals
Indicator
CXM
LTGO
Relative Strength Index (RSI) 64.08 35.92
Support Level $5.57 N/A
Resistance Level $8.28 $16.56
Average True Range (ATR) 0.21 1.21
MACD 0.14 -0.13
Stochastic Oscillator 95.93 19.74

Price Performance

Historical Comparison
CXM
LTGO

About CXM Sprinklr Inc.

Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale, all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights, and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.

About LTGO Latigo Biotherapeutics Inc. Common Stock

Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.

Share on Social Networks: